Cilo Cybin expects full-year loss per share of 95.88-96.05 cents on IFRS 2 listing expense

• Cilo Cybin flagged a sharp swing to a full-year loss, driven by an IFRS 2 listing expense of ZAR 217.48 million.
• EPS is expected at a loss of 95.88 to 96.05 cents, versus a reported loss of 0.85 cents a year earlier.
• HEPS is expected at a loss of 95.88 to 96.05 cents, versus a reported loss of 0.85 cents previously.
• Prior-year EPS and HEPS will be restated to 9.49 cents under reverse acquisition accounting tied to the CC Pharmaceutical deal.
• Annual results are expected on or about Aug. 28, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cilo Cybin Holdings Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S525454), on August 12, 2026, and is solely responsible for the information contained therein.